GC Biopharma submits IND to begin Phase 3 Clinical Trial for BARYCELA in Thailand ...Middle East

YONGIN, South Korea, Aug. 28, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application to the Thailand Food and Drug Administration (FDA) to initiate a Phase 3 clinical trial...

Hence then, the article about gc biopharma submits ind to begin phase 3 clinical trial for barycela in thailand was published today ( Thursday 28/08/2025 - 09:23 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( GC Biopharma submits IND to begin Phase 3 Clinical Trial for BARYCELA in Thailand )

Also on site :

• Human heads displayed at Ecuador tourist beach in warning to gangs
• Nazi salutes and drug cartels: Dutch mercenary recounts service with Kiev’s military
• Allegiant and Sun Country Airlines to Combine, Creating a Leading, More Competitive Leisure-Focused U.S. Airline